AstraZeneca, Gilead get a new challenger as Pyramid deviates from TRK to bag antibody-drug conjugate
17 Apr 2023
ADCPhase 3
Preview
Source: FierceBiotech
Pyramid Biosciences sees opportunities for an antibody-drug conjugate across breast, lung, pancreatic, ovarian and prostate cancers.
Pyramid Biosciences’ current pipeline is built around the kinase TRK. But the biotech has now struck a deal that will take it down a new path, paying $20 million upfront and betting $1 billion in biobucks for the ex-greater China rights to a would-be challenger to Gilead’s antibody-drug conjugate (ADC) Trodelvy.
New Jersey-based Pyramid is giving GeneQuantum Healthcare the money in return for a TROP2-directed ADC, GQ1010. The drug candidate “has shown a highly differentiated preclinical profile,” Pyramid said, and is on course to enter the clinic in the next year. GeneQuantum used a novel site-specific conjugation technology and linker-payload in GQ1010 to increase its stability, safety and potency.
Gilead paid $21 billion to buy Immunomedics for the first-in-class, TROP2-directed ADC Trodelvy in 2020. Sales of the drug increased (PDF) 79% last year, climbing to $680 million, as Gilead made inroads into the U.S. and European breast cancer markets. AstraZeneca, which paid Daiichi Sankyo to co-develop a TROP2 ADC in 2020, is threatening to curb Gilead’s progress with a rival therapy that is in phase 3 development.
The presence of commercial products and advanced clinical candidates, in the hands of deep-pocketed drugmakers, has failed to dissuade Pyramid from trying to make its mark on the TROP2 market. Pyramid sees a range of opportunities for the ADC across breast, lung, pancreatic, ovarian and prostate cancers.
Bolting GQ1010 onto the pipeline moves Pyramid outside of its traditional area of focus. Prior to the ADC deal, the biotech constructed a pipeline around its knowledge of TRK, taking its pan-TRK kinase inhibitorTRK kinase inhibitor PBI-200 into the clinic in solid tumors and joining the small club of companies to explore the potential of the target in dermatological conditions such as psoriasis.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.